Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy
J. A. M. J. L. Janssen, FM van der Toorn, Leo J. Hofland et al.
Research Article — Peer-Reviewed Source
Original research published by Janssen et al. in European Journal of Endocrinology. Redistributed under Open Access — see publisher for license terms. MedTech Research Group provides these references for informational purposes. We do not conduct original research. All studies are the work of their respective authors and institutions.
We did not observe elevated ghrelin levels in adult GHD subjects and GH replacement therapy did not modify circulating ghrelin levels, despite significant decreases in body fat mass and percentage body fat. It is conceivable that the lack of ghrelin modifications after long-term GH therapy was due to the reduction of adiposity and insulin on one hand, and increased GH secretion on the other. However, it is still possible that systemic ghrelin is involved in the development of obesity, both in normal and GHD subjects.
Full text is available at the publisher.
Read at Publisher| DOI | 10.1530/eje.0.1450711 |
| Journal | European Journal of Endocrinology |
| Year | 2001 |
| Authors | J. A. M. J. L. Janssen, FM van der Toorn, Leo J. Hofland, Peter van Koetsveld, Fabio Broglio, Ezio Ghigo, SW Lamberts, Aart Jan van der Lely |
| License | Open Access — see publisher for license terms |
| Citations | 113 |